Anzeige
Mehr »
Login
Mittwoch, 21.04.2021 Börsentäglich über 12.000 News von 660 internationalen Medien
East Africa Metals: Endlich! Ist das der Startschuss?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0F57T ISIN: JP3475350009 Ticker-Symbol: D4S 
Tradegate
20.04.21
21:30 Uhr
22,390 Euro
-0,550
-2,40 %
Branche
Pharma
Aktienmarkt
NIKKEI-225
1-Jahres-Chart
DAIICHI SANKYO CO LTD Chart 1 Jahr
5-Tage-Chart
DAIICHI SANKYO CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
22,42023,07009:07
22,43023,09009:07

Aktuelle News zur DAIICHI SANKYO Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DAIICHI SANKYO Aktie jetzt für 0€ handeln
DiDaiichi Sankyo UK, Limited: ENHERTU - (TRASTUZUMAB DERUXTECAN) NOW AVAILABLE VIA THE CANCER DRUGS FUND FOR THE TREATMENT OF HER2 POSITIVE METASTATIC BREAST CANCER214For UK media ONLY NICE decision based on results from the DESTINY-Breast01 trial Reimbursement decisions in Scotland, Wales, and Northern Ireland to be announced later this year Daiichi...
► Artikel lesen
09.04.Fierce Pharma Asia-Takeda-CSL COVID fail; Daiichi Sankyo's new 5-year plan; Legend-J&J CAR-T filing14
07.04.Daiichi Sankyo Company, Limited: Phase 1/2 Trial Initiated for Daiichi Sankyo's Menin Inhibitor DS-1594 in Patients with Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia223Daiichi Sankyo Company, Limited (hereafter Daiichi Sankyo) today announced the first patient has been dosed in the first-in-human phase 1/2 study of DS-1594, a selective small-molecule menin inhibitor...
► Artikel lesen
06.04.Daiichi Sankyo Company, Limited: DESTINY-CRC02 Phase 2 Trial of ENHERTU Initiated in Patients with HER2 Overexpressing Advanced Colorectal Cancer308Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today announced that the first patient was dosed in DESTINY-CRC02, a global phase 2 trial evaluating the efficacy and safety...
► Artikel lesen
29.03.Daiichi Sankyo Company, Limited: DESTINY-Lung02 Phase 2 Trial of ENHERTU Initiated in Patients with HER2 Mutated Metastatic Non-Small Cell Lung Cancer310Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today announced the first patient was dosed in DESTINY-Lung02, a global phase 2 trial evaluating the safety and efficacy...
► Artikel lesen
23.03.Daiichi Sankyo inks digital partnership for atrial fibrillation2
22.03.Daiichi Sankyo, KM Biologics Start COVID Vaccine Trials4
18.03.UK approval for Daiichi Sankyo's cholesterol-lowering treatments2
24.02.Daiichi Sankyo Company, Limited: Daiichi Sankyo and LYSA-LYSARC-CALYM Enter Research Collaboration for Valemetostat in Patients with Relapsed/Refractory B-Cell Lymphoma282Phase 2 trial to evaluate valemetostat in patients with five disease subtypes along with a planned robust translational research program Daiichi Sankyo Company, Limited (hereafter, Daiichi...
► Artikel lesen
22.02.Daiichi Sankyo Company, Limited: Daiichi Sankyo ernennt Dr. Ken Takeshita zum Global Head of R&D308Daiichi Sankyo Company, Limited (nachfolgend Daiichi Sankyo) gab heute die Ernennung von Dr. Ken Takeshita zum neuen Global Head of Research Development mit Wirkung zum 1. April 2021 bekannt. Zu diesem...
► Artikel lesen
22.02.Kite development head Ken Takeshita jumps to Daiichi Sankyo amid oncology push1
22.02.Daiichi Sankyo poaches Kite's research lead Takeshita from parent Gilead49
22.02.Daiichi Sankyo Company, Limited: Daiichi Sankyo Appoints Ken Takeshita, MD as Global Head of R&D202Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced Ken Takeshita, MD will be named the new Global Head of Research Development as of April 1, 2021. On that date, Dr. Junichi...
► Artikel lesen
21.02.Takeda and Daiichi Sankyo to begin COVID-19 vaccine trials in Japan19
16.02.AZ, Daiichi Sankyo's Enhertu scores approval in the UK-
16.02.Daiichi Sankyo UK, Limited: ENHERTU - (TRASTUZUMAB DERUXTECAN) AUTHORISED IN THE UK FOR THE TREATMENT OF HER2 POSITIVE METASTATIC BREAST CANCER267For UK media ONLY Marketing Authorisation based on the DESTINY-Breast01 trial (16 February, 2021) Daiichi Sankyo UK, Limited(hereafter, Daiichi Sankyo) and AstraZeneca UK's Enhertu (trastuzumab...
► Artikel lesen
03.02.Daiichi Sankyo Company, Limited: HERTHENA-Lung01 Phase 2 Study of Daiichi Sankyo's Patritumab Deruxtecan Initiated in Patients with EGFR-Mutated NSCLC320Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the first patient has been dosed in HERTHENA-Lung01, a phase 2 study evaluating patritumab deruxtecan, a HER3 directed...
► Artikel lesen
02.02.James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #636
02.02.Daiichi Sankyo Company, Limited: Daiichi Sankyo Initiates Clinical Development of Sixth DXd ADC DS-6000 with Sarah Cannon Research Institute306Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Sarah Cannon Research Institute (Sarah Cannon) announced today that the first patient has been dosed in the first-in-human phase 1 study...
► Artikel lesen
02.02.Daiichi Sankyo Co Ltd (DSKYF) Q3 2020 Results - Earnings Call Transcript3
Seite:  Weiter >>
89 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2